🔗 Share this article

While America continues making sweeping changes to its vaccination guidelines, a particular individual has surfaced unexpectedly: Høeg, a Danish American physician and public health researcher who rose to prominence by questioning Covid vaccines in the global health crisis and has focused upon possible fatalities after COVID-19 immunization in her brief tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Public health authorities had intended to reveal radical revisions to the childhood vaccination calendar in December, bringing the US with Denmark’s national calendar, according to reports – a substantial departure that would place the US at odds with a large portion of the world with insufficient data for improved outcomes. The planned update has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is scheduled to speak at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood immunization guidelines in the US to become more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – traditionally the domain of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Background

Høeg has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been standard for past heads of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Past heads of the center would “grasp regulatory frameworks and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who headed CBER have had.”

This division has an immense workload at the agency, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the generic program clears a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one have to be supervised,” Dr. Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant management aspect to the job, which oversees in excess of 5,000 personnel. “It’s a massive management job, if you execute it properly,” Woodcock said.

Response and Disputed Programs

When asked about questions about Høeg’s fitness for the role and whether this selection represents greater collaboration among FDA leaders on immunizations, a press secretary said that the “inquiries are based on incorrect premises”.

“Her experience matches the functions of her role,” the representative explained, noting the months Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg takes over the agency head's new expedited review system, a controversial rapid medication authorization process that apparently troubled her predecessors. “By what process are these drugs being picked for this fast-track system? Who is making the calls?” Dr. Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of pharmaceuticals, with the exception of vaccines.”

Established Past Work on Vaccines

Concerning vaccines, Høeg has a more established, if troubling, past, critics observe. She released a analysis using non-validated public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the new federal leadership encompassed revising regulations for recently developed shots and ending “unnecessary” immunizations, she said post-election on a audio program. At the FDA, Dr. Høeg has allegedly proposed excluding adolescent males from receiving Covid vaccinations.

“She’s an complete dogmatist who begins with her beliefs and reverse-engineers to fit the science in a highly misleading, untruthful manner,” Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|